ATIVIDADE DA ENZIMA E-NTPDase E PARÂMETROS HEMATOLÓGICOS EM PACIENTES JOVENS COM LEUCEMIA LINFOBLÁSTICA AGUDA

Detalhes bibliográficos
Autor(a) principal: Flávia Castro Souto
Data de Publicação: 2022
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Repositório Institucional da UFMS
Texto Completo: https://repositorio.ufms.br/handle/123456789/4641
Resumo: Leukemias are hematological neoplasms that result from the clonal expansion of stem cells. The blood count is part of the routine investigation of a patient suspected of having leukemia. Leukemic cells proliferate disorderly in the bone marrow replacing normal hematopoietic cells, reflecting changes in the blood count. Studies show that patients with leukemia have changes in hematological parameters at diagnosis and also changes in the purinergic system. The purinergic system participates in several cellular functions, such as cell proliferation and cell death. E-NTPDase regulates the levels of ATP and ADP nucleotides that act as agonists for receptors that play an important role in tumor development and progression. In this context, the aim of this study was to evaluate the basic hematological parameters of peripheral blood, the activity of the E-NTPDase enzyme in bone marrow mononuclear cells and the membrane markers of young people with type B acute lymphoblastic leukemia. A total of 22 patients and divided into two groups: high risk (RA) and intermediate risk and low risk (RI/BR) of disease recurrence. The 22 patients had hematological parameters, number of leukocytes, hemoglobin content and number of platelets analyzed in the induction phase of treatment. E-NTPDase activity was analyzed in 11 patients at various stages of treatment and membrane markers, present in cell populations at diagnosis, were analyzed in 19 patients. Regarding the reference values of the blood count, the number of leukocytes, at diagnosis, of patients classified as RA was significantly high and patients in the RI/BR group also showed an increase, but closer to the limit of the reference value (10,000 /mm3). Such an increase is caused by the excessive proliferation of leukemic cells in the bone marrow that spreads to the peripheral blood presenting this alteration. This disordered proliferation of leukocytes decreases the production of erythrocytes and platelets. The two groups of patients in this study had, at diagnosis, low hemoglobin (Hb) and platelet numbers. The activity of E-NTPDase in the hydrolysis of ATP and ADP, in the cells of patients classified as RI/BR of disease recurrence, were higher compared to patients in the RA group. These findings differ from those found in the literature. Among the membrane markers present, three patients had a mutation in the CRLF2 gene. The results obtained in this study add to others found in the literature. Future experiments are needed to elucidate the profile of the purinergic system in patients with leukemias.
id UFMS_3035d4a3ee4d5e49435b9f34f71ce136
oai_identifier_str oai:repositorio.ufms.br:123456789/4641
network_acronym_str UFMS
network_name_str Repositório Institucional da UFMS
repository_id_str 2124
spelling 2022-04-01T20:54:21Z2022-04-01T20:54:21Z2022https://repositorio.ufms.br/handle/123456789/4641Leukemias are hematological neoplasms that result from the clonal expansion of stem cells. The blood count is part of the routine investigation of a patient suspected of having leukemia. Leukemic cells proliferate disorderly in the bone marrow replacing normal hematopoietic cells, reflecting changes in the blood count. Studies show that patients with leukemia have changes in hematological parameters at diagnosis and also changes in the purinergic system. The purinergic system participates in several cellular functions, such as cell proliferation and cell death. E-NTPDase regulates the levels of ATP and ADP nucleotides that act as agonists for receptors that play an important role in tumor development and progression. In this context, the aim of this study was to evaluate the basic hematological parameters of peripheral blood, the activity of the E-NTPDase enzyme in bone marrow mononuclear cells and the membrane markers of young people with type B acute lymphoblastic leukemia. A total of 22 patients and divided into two groups: high risk (RA) and intermediate risk and low risk (RI/BR) of disease recurrence. The 22 patients had hematological parameters, number of leukocytes, hemoglobin content and number of platelets analyzed in the induction phase of treatment. E-NTPDase activity was analyzed in 11 patients at various stages of treatment and membrane markers, present in cell populations at diagnosis, were analyzed in 19 patients. Regarding the reference values of the blood count, the number of leukocytes, at diagnosis, of patients classified as RA was significantly high and patients in the RI/BR group also showed an increase, but closer to the limit of the reference value (10,000 /mm3). Such an increase is caused by the excessive proliferation of leukemic cells in the bone marrow that spreads to the peripheral blood presenting this alteration. This disordered proliferation of leukocytes decreases the production of erythrocytes and platelets. The two groups of patients in this study had, at diagnosis, low hemoglobin (Hb) and platelet numbers. The activity of E-NTPDase in the hydrolysis of ATP and ADP, in the cells of patients classified as RI/BR of disease recurrence, were higher compared to patients in the RA group. These findings differ from those found in the literature. Among the membrane markers present, three patients had a mutation in the CRLF2 gene. The results obtained in this study add to others found in the literature. Future experiments are needed to elucidate the profile of the purinergic system in patients with leukemias.Leucemias são neoplasias hematológicas que resultam da expansão clonal de células-tronco. O hemograma faz parte da rotina de investigação de um paciente com suspeita de ter leucemia. As células leucêmicas proliferam-se de forma desordenada na medula óssea substituindo células hematopoiéticas normais, refletindo alterações no hemograma. Estudos mostram que os pacientes com leucemia apresentam alteração nas parâmetros hematológicos no diagnóstico e também alteração no sistema purinérgico. O sistema purinérgico participa de diversas funções celulares, como proliferação e morte celular. A E-NTPDase regula os níveis dos nucleotídeos ATP e ADP que atuam como agonistas para receptores que desempenham um importante papel no desenvolvimento e progressão tumoral. Nesse contexto, o objetivo deste estudo foi avaliar os parâmetros hematológicos básicos do sangue periférico, a atividade da enzima E-NTPDase em células mononucleares da medula óssea e os marcadores de membrana de jovens com leucemia linfoblástica aguda do tipo B. Foram incluídos um total de 22 pacientes e divididos em dois grupos: alto risco (AR) e risco intermediário e baixo risco (RI/BR) de recidiva da doença. Os 22 pacientes tiveram os parâmetros hematológicos, número de leucócitos, conteúdo de hemoglobina e número de plaquetas, analisados na fase de indução do tratamento. A atividade de E-NTPDase foi analisada em 11 pacientes em várias etapas do tratamento e os marcadores de membrana, presentes nas populações celulares no diagnóstico, foram analisados em 19 pacientes. Em relação aos valores de referência do hemograma, o número de leucócitos, no diagnóstico, dos pacientes classificados como AR mostrou-se significativamente alto e dos pacientes do grupo RI/BR também apresentaram elevação, porém mais próximo do limite do valor de referência (10.000/mm3). Tal aumento é causado pela proliferação excessiva de células leucêmicas na medula óssea que se espalha para o sangue periférico apresentando esta alteração. Essa proliferação desordenada de leucócitos diminui a produção de eritrócitos e plaquetas. Os dois grupos de pacientes deste estudo apresentaram, no diagnóstico, conteúdo de hemoglobina (Hb) e número de plaqueta baixos. A atividade de E-NTPDase na hidrólise de ATP e ADP, nas células dos pacientes classificados como RI/BR de recidiva da doença, foram maiores em relação aos pacientes do grupo AR. Esses achados diferem dos encontrados na literatura. Entre os marcadores de membrana presentes, três pacientes apresentaram presença da mutação no gene CRLF2. Os resultados obtidos neste estudo somam à outros encontrados na literatura. Experimentos futuros são necessários para elucidar o perfil do sistema purinérgico em pacientes com leucemias.Fundação Universidade Federal de Mato Grosso do SulUFMSBrasilLeucemia. Sistema purinérgico. Ectonucleotidases.ATIVIDADE DA ENZIMA E-NTPDase E PARÂMETROS HEMATOLÓGICOS EM PACIENTES JOVENS COM LEUCEMIA LINFOBLÁSTICA AGUDAinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisJeandre Augusto dos Santos JaquesFlávia Castro Soutoinfo:eu-repo/semantics/openAccessporreponame:Repositório Institucional da UFMSinstname:Universidade Federal de Mato Grosso do Sul (UFMS)instacron:UFMSTHUMBNAIL2022 03 12 Dissertação final - Flávia.pdf.jpg2022 03 12 Dissertação final - Flávia.pdf.jpgGenerated Thumbnailimage/jpeg1193https://repositorio.ufms.br/bitstream/123456789/4641/3/2022%2003%2012%20Disserta%c3%a7%c3%a3o%20final%20-%20Fl%c3%a1via.pdf.jpgc503029787e5e1abf16ab1472cee1a34MD53TEXT2022 03 12 Dissertação final - Flávia.pdf.txt2022 03 12 Dissertação final - Flávia.pdf.txtExtracted texttext/plain94838https://repositorio.ufms.br/bitstream/123456789/4641/2/2022%2003%2012%20Disserta%c3%a7%c3%a3o%20final%20-%20Fl%c3%a1via.pdf.txtad0cc63aa8f51c85653ef3d4841f36f7MD52ORIGINAL2022 03 12 Dissertação final - Flávia.pdf2022 03 12 Dissertação final - Flávia.pdfapplication/pdf814587https://repositorio.ufms.br/bitstream/123456789/4641/1/2022%2003%2012%20Disserta%c3%a7%c3%a3o%20final%20-%20Fl%c3%a1via.pdf1552fe12baa577e147bdc9408e6da38fMD51123456789/46412022-04-02 03:01:29.704oai:repositorio.ufms.br:123456789/4641Repositório InstitucionalPUBhttps://repositorio.ufms.br/oai/requestri.prograd@ufms.bropendoar:21242022-04-02T07:01:29Repositório Institucional da UFMS - Universidade Federal de Mato Grosso do Sul (UFMS)false
dc.title.pt_BR.fl_str_mv ATIVIDADE DA ENZIMA E-NTPDase E PARÂMETROS HEMATOLÓGICOS EM PACIENTES JOVENS COM LEUCEMIA LINFOBLÁSTICA AGUDA
title ATIVIDADE DA ENZIMA E-NTPDase E PARÂMETROS HEMATOLÓGICOS EM PACIENTES JOVENS COM LEUCEMIA LINFOBLÁSTICA AGUDA
spellingShingle ATIVIDADE DA ENZIMA E-NTPDase E PARÂMETROS HEMATOLÓGICOS EM PACIENTES JOVENS COM LEUCEMIA LINFOBLÁSTICA AGUDA
Flávia Castro Souto
Leucemia. Sistema purinérgico. Ectonucleotidases.
title_short ATIVIDADE DA ENZIMA E-NTPDase E PARÂMETROS HEMATOLÓGICOS EM PACIENTES JOVENS COM LEUCEMIA LINFOBLÁSTICA AGUDA
title_full ATIVIDADE DA ENZIMA E-NTPDase E PARÂMETROS HEMATOLÓGICOS EM PACIENTES JOVENS COM LEUCEMIA LINFOBLÁSTICA AGUDA
title_fullStr ATIVIDADE DA ENZIMA E-NTPDase E PARÂMETROS HEMATOLÓGICOS EM PACIENTES JOVENS COM LEUCEMIA LINFOBLÁSTICA AGUDA
title_full_unstemmed ATIVIDADE DA ENZIMA E-NTPDase E PARÂMETROS HEMATOLÓGICOS EM PACIENTES JOVENS COM LEUCEMIA LINFOBLÁSTICA AGUDA
title_sort ATIVIDADE DA ENZIMA E-NTPDase E PARÂMETROS HEMATOLÓGICOS EM PACIENTES JOVENS COM LEUCEMIA LINFOBLÁSTICA AGUDA
author Flávia Castro Souto
author_facet Flávia Castro Souto
author_role author
dc.contributor.advisor1.fl_str_mv Jeandre Augusto dos Santos Jaques
dc.contributor.author.fl_str_mv Flávia Castro Souto
contributor_str_mv Jeandre Augusto dos Santos Jaques
dc.subject.por.fl_str_mv Leucemia. Sistema purinérgico. Ectonucleotidases.
topic Leucemia. Sistema purinérgico. Ectonucleotidases.
description Leukemias are hematological neoplasms that result from the clonal expansion of stem cells. The blood count is part of the routine investigation of a patient suspected of having leukemia. Leukemic cells proliferate disorderly in the bone marrow replacing normal hematopoietic cells, reflecting changes in the blood count. Studies show that patients with leukemia have changes in hematological parameters at diagnosis and also changes in the purinergic system. The purinergic system participates in several cellular functions, such as cell proliferation and cell death. E-NTPDase regulates the levels of ATP and ADP nucleotides that act as agonists for receptors that play an important role in tumor development and progression. In this context, the aim of this study was to evaluate the basic hematological parameters of peripheral blood, the activity of the E-NTPDase enzyme in bone marrow mononuclear cells and the membrane markers of young people with type B acute lymphoblastic leukemia. A total of 22 patients and divided into two groups: high risk (RA) and intermediate risk and low risk (RI/BR) of disease recurrence. The 22 patients had hematological parameters, number of leukocytes, hemoglobin content and number of platelets analyzed in the induction phase of treatment. E-NTPDase activity was analyzed in 11 patients at various stages of treatment and membrane markers, present in cell populations at diagnosis, were analyzed in 19 patients. Regarding the reference values of the blood count, the number of leukocytes, at diagnosis, of patients classified as RA was significantly high and patients in the RI/BR group also showed an increase, but closer to the limit of the reference value (10,000 /mm3). Such an increase is caused by the excessive proliferation of leukemic cells in the bone marrow that spreads to the peripheral blood presenting this alteration. This disordered proliferation of leukocytes decreases the production of erythrocytes and platelets. The two groups of patients in this study had, at diagnosis, low hemoglobin (Hb) and platelet numbers. The activity of E-NTPDase in the hydrolysis of ATP and ADP, in the cells of patients classified as RI/BR of disease recurrence, were higher compared to patients in the RA group. These findings differ from those found in the literature. Among the membrane markers present, three patients had a mutation in the CRLF2 gene. The results obtained in this study add to others found in the literature. Future experiments are needed to elucidate the profile of the purinergic system in patients with leukemias.
publishDate 2022
dc.date.accessioned.fl_str_mv 2022-04-01T20:54:21Z
dc.date.available.fl_str_mv 2022-04-01T20:54:21Z
dc.date.issued.fl_str_mv 2022
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://repositorio.ufms.br/handle/123456789/4641
url https://repositorio.ufms.br/handle/123456789/4641
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Fundação Universidade Federal de Mato Grosso do Sul
dc.publisher.initials.fl_str_mv UFMS
dc.publisher.country.fl_str_mv Brasil
publisher.none.fl_str_mv Fundação Universidade Federal de Mato Grosso do Sul
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFMS
instname:Universidade Federal de Mato Grosso do Sul (UFMS)
instacron:UFMS
instname_str Universidade Federal de Mato Grosso do Sul (UFMS)
instacron_str UFMS
institution UFMS
reponame_str Repositório Institucional da UFMS
collection Repositório Institucional da UFMS
bitstream.url.fl_str_mv https://repositorio.ufms.br/bitstream/123456789/4641/3/2022%2003%2012%20Disserta%c3%a7%c3%a3o%20final%20-%20Fl%c3%a1via.pdf.jpg
https://repositorio.ufms.br/bitstream/123456789/4641/2/2022%2003%2012%20Disserta%c3%a7%c3%a3o%20final%20-%20Fl%c3%a1via.pdf.txt
https://repositorio.ufms.br/bitstream/123456789/4641/1/2022%2003%2012%20Disserta%c3%a7%c3%a3o%20final%20-%20Fl%c3%a1via.pdf
bitstream.checksum.fl_str_mv c503029787e5e1abf16ab1472cee1a34
ad0cc63aa8f51c85653ef3d4841f36f7
1552fe12baa577e147bdc9408e6da38f
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFMS - Universidade Federal de Mato Grosso do Sul (UFMS)
repository.mail.fl_str_mv ri.prograd@ufms.br
_version_ 1807552861044736000